Status:
COMPLETED
Alpha Lipoic Acid Effect on No-Reflow Phenomenon
Lead Sponsor:
Ain Shams University
Conditions:
No-Reflow Phenomenon
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Prospective, randomized, open-label, controlled clinical trial to evaluate the efficacy and tolerability of Alpha Lipoic Acid administration on oxidative stress, inflammatory markers, clinical outcome...
Detailed Description
All (70) STEMI patients undergoing PCI presenting to the Cardiology department will be randomly assigned into one of 2 arms: 35 patients undergoing PCI who will receive standard of care , the other 35...
Eligibility Criteria
Inclusion
- Female or male aged \>18
- STEMI patients undergoing PCI
Exclusion
- Patients with a recent history of myocardial infarction (MI), a previous PCI or a previous coronary artery bypass graft
- A late presentation (\>12 h), unsuccessful primary PCI (residual stenosis \>50% in the culprit lesion after procedure)
- Pretreatment with thrombolytic or glycoprotein IIb/IIIa inhibitor therapy before primary PCI
- Infectious or inflammatory disease
- Severe liver or renal disease, (AST or ALT \>3x ULN or Total bilirubin \>2.5 x ULN), (CrCl \< 60 ml/min (based on the Cockroft-Gault equation)
- Neoplasm, or hematological disorders
- Pregnant or breast-feeding patients
- Active participation in another clinical study
- Patients taking Alpha Lipoic Acid.
- Systolic Blood pressure \<90
Key Trial Info
Start Date :
January 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2024
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT05360602
Start Date
January 1 2022
End Date
January 31 2024
Last Update
November 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain shams hospitals
Cairo, Egypt